GlassScriptPhysician profile
Gary S Schenk
NPI 1417021254
$6,952.29
in general payments reported to CMS, 2019-2025
38 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $1,342 · 2021: $1,804 · 2022: $1,211 · 2023: $277 · 2024: $192 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $779.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $735.71 | 2019-2025 | Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $670.42 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $519.56 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $412.79 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $370.07 | 2019-2022 | |
| Astellas Pharma US INC | $344.98 | 2019-2023 | Myrbetriq |
| Amgen INC. | $337.84 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $263.65 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $260.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $249.42 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Allergan, INC. | $243.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $238.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.64 | 2019-2024 | Synjardy, Jardiance |
| Amarin Pharma, INC. | $147.04 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Schenk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.